在阿尔茨海默氏病小鼠模型中,APP调节器RHBDL4的损失可以保存记忆
Ylauna Christine Mégane Penalva1,2,3,4, Sandra Paschkowsky1,3, Jingyun Yang5,6
1Department of Pharmacology & Therapeutics, McGill University, Montreal, QC, Canada.
Cell death & disease
|April 12, 2025
概括
状蛋白酶4 (RHBDL4) 在阿尔茨海默病 (AD) 中被上调,通过降解β-catenin,导致认知能力下降. 它的缺席通过保持β-catenin水平,在AD模型中意外地改善了认知.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 涉及大脑病理,内质网膜 (ER) 压力和神经退行.
- 展开的蛋白质反应 (UPR) 被激活以维持ER稳态.
- 形状蛋白酶4 (RHBDL4) 是一种ER-居民蛋白酶,参与了UPR,向蛋白质进行降解.
研究的目的:
- 研究RHBDL4在大脑中的生理作用,特别是在阿尔茨海默病中.
- 为了确定RHBDL4缺乏对粉样蛋白前体蛋白 (APP) 处理和认知功能 in vivo的影响.
主要方法:
- 在人类AD大脑样本和AD小鼠模型 (APPtg) 中分析RHBDL4表达.
- 生产RHBDL4淘汰 (R4-/-) 和APPTg小鼠交叉,以创建一个双变异模型.
- 通过RNA-seq,体外和体内实验评估APP水平,粉胺基因处理,认知功能和β-catenin水平.
主要成果:
- 在AD大脑和APPTg小鼠中,RHBDL4表达升高.
- 在APPtg小鼠中RHBDL4缺乏增加了大脑APP和amyloidogenic处理.
- 缺少RHBDL4在年轻的雌性APPtg小鼠中挽救了认知缺陷,与由于减少蛋白质体降解而增加的活性β-catenin水平有关.
结论:
- 在AD中增加RHBDL4表达,通过促进APP处理和异常β-catenin降解,有助于认知障碍.
- RHBDL4在AD病变发生过程中起着复杂的作用,影响APP代谢和β-catenin信号传递.
- 向RHBDL4可能通过调节APP和β-catenin通路来提供AD的治疗策略.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
328
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
328
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K


